Sirius Medical has raised €4.4 million ($4.9 million) as it seeks to commercialize its Sirius Pintuition non-radioactive tumor localization system.
News of the money raise comes about a month after the Eindhoven, the Netherlands-based Sirius announced that it had won a CE Mark for the system. FDA clearance is pending.
The Series A round was led by BOM Brabant Ventures, with co-investors Curie Capital and Holland Capital. Additional funding came from the Dutch Research Council (NWO) and the Mibiton Foundation, plus local development agencies, business angels, management and existing shareholders of Sirius.
“We are grateful for the trust provided by our investors in the Sirius Medical team. The A-round funding enables Sirius Medical to execute on its ambitious growth plans; delivering superior localization technology to our customers and developing our further pipeline of solutions,” CEO Hubert Martens said in a news release.